Investigation of the gut as a possible reservoir for the JC Polyoma virus in patients with multiple sclerosis under treatment with natalizumab

Investigation of the gut as a possible reservoir for the JC Polyoma virus in patients with multiple sclerosis under treatment with natalizumab - JCV-G

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017542

Enrollment

Registered

2019-07-31

Start date

2019-06-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A81.2

Interventions

Group 1: In order to analyze the question we are planning to include 40 patients, which are currently under natalizumab treatment at the department of neurology in the University clinic of Cologne and

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: multiple sclerosis patients under treatment with natalizumab, signed form of consent

Exclusion criteria

Exclusion criteria: consent denied

Design outcomes

Primary

Measure	Time frame
Identification of the JCPyVirus in stool, blood and urine samples during treatment with natalizumab. When patients arrive in the clinic to receive their treatement, blood and urine samples will be obtained right away. In the days following the infusion a stool sample will be sent to the clinic by the patient.	—

Secondary

Measure	Time frame
Quantitative and qualitative analysis of the Virus DNA in the stool, blood and urine samples.	—

Countries

Germany

Contacts

Public ContactClemens Warnke

University Clinic of Cologne

clemens.warnke@uk-koeln.de0221 478 6188

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026